Liver Triglyceride Content in HIV-1-Infected Patients on Combination Antiretroviral Therapy Studied with <sup>1</sup>H-MR Spectroscopy

Antiviral Therapy - Tập 12 Số 2 - Trang 195-204 - 2007
Àngel Moreno‐Torres1, Peré Domingo2, Jesús Pujol Salud3,1, Francisco Blanco‐Vaca4, Juan Antonio Arroyo2, M. A. Sambeat4,2
1Research Department, Centre Diagnòstic Pedralbes, Esplugues de Llobregat, Spain
2Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
3Institut d'Alta Tecnologia, CRC Corporació Sanitària, Barcelona, Spain
4Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Tóm tắt

Objective To carry out an exploratory evaluation of liver triglyceride content in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART) using proton magnetic resonance spectroscopy and to study how both the treatment itself and the biochemical and physiological variables in which the treatment causes alterations are related to liver fat content. Methods Intracellular hepatic triglyceride content was determined in 29 HIV-1-infected patients on their first HAART regime by means of localized water-unsuppressed single voxel proton spectra. Other measurements were body mass index, waist-to-hip ratio, lipodystrophy assessment and a detailed blood biochemical analysis. The relationship between intracellular hepatic triglycerides and relevant descriptive, treatment and biochemical variables was studied by correlation and regression analysis. Results Intrahepatic triglycerides were detected in 58.6% of the patients and 13.8% showed a triglyceride content compatible with liver steatosis. Many variables (body mass index, waist-to-hip ratio, cumulative exposure to PIs, lactate, insulin, insulin resistance measured by the homeostasis model assessment method [HOMA-R index], pH, total triglycerides, high density lipoprotein cholesterol and very low density lipoprotein [VLDL] cholesterol) correlated individually with the amount of triglycerides. Stepwise multiple regression analysis showed that the combination of insulin or HOMA-R index and VLDL cholesterol accounted for up to 50.2% of the triglyceride liver variance. A positive relationship was found between the concomitant presence of the metabolic syndrome components (insulin resistance, dyslipidaemia and central obesity) and intrahepatic triglyceride content. Conclusions The study showed that intrahepatic triglyceride deposit appears to be a frequent feature of HIV-1-infected patients receiving HAART. A coherent multifactorial combination of biochemical and physiological factors associated with the deposit suggested that cumulative exposure to PIs might be a possible trigger event.

Từ khóa


Tài liệu tham khảo

10.1038/nrd1151

Montessori V., 2004, Can Med Assoc J, 170, 229

10.2337/diab.37.12.1595

10.2337/diacare.25.7.1253

10.2337/diacare.24.4.683

10.2337/diab.41.6.715

10.1086/313912

10.1097/00002030-200211080-00011

10.1016/j.cld.2004.04.008

10.1097/00004424-199304000-00006

10.1016/0730-725X(94)92543-7

Szczepaniak L.S., 1999, Am J Physiol, 276, E977

10.1152/ajpendo.00064.2004

10.1210/jc.2004-1983

10.1194/jlr.M200342-JLR200

10.1161/01.ATV.0000116217.57583.6e

10.1016/S0002-9343(99)00271-5

10.2337/diabetes.50.8.1844

10.2337/diabetes.49.5.749

10.1093/ajcn/64.5.685

10.1097/00002030-199911120-00007

10.1007/BF00280883

10.1016/S0025-7753(01)72168-9

10.1016/S0953-6205(03)00022-0

10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

10.1002/mrm.1910230118

Frahm J., 1987, J Magn Reson, 72, 502

10.1016/j.neurobiolaging.2004.09.009

10.1002/mrm.10560

10.1002/mrm.1910060111

10.1007/BF01070758

Piroth L., 2005, AIDS Rev, 7, 197

Pares A., 2000, Med Clin (Barc), 114, 561, 10.1016/S0025-7753(00)71364-9

10.1097/00042737-200603000-00002

10.1097/01.aids.0000163935.99401.25

10.1016/0026-0495(93)90210-F

10.1002/hep.510300604

10.1016/S0163-7827(01)00013-3

10.2165/00003495-200363230-00001

10.1016/j.atherosclerosis.2004.07.035

10.1074/jbc.M104557200

10.1038/ncpgasthep0084

10.1086/313921

10.2337/diacare.23.1.57

10.2337/diacare.28.9.2289

10.1016/S0140-6736(05)67402-8

Thông tin
Thông tin xuất bản

Antiviral Therapy

Tập 12 Số 2

195-204

Thông tin tác giả